# SBC Medical Group Holdings Inc: overview
SBC · Nasdaq · CIK 1930313 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31
Pages: [Overview](/companies/sbc.md) · [Financials](/companies/sbc/financials.md) · [Filings](/companies/sbc/filings.md) · [Insiders](/companies/sbc/insiders.md)
Latest reported revenue: [$49.2m](/filings/0001193125-26-347843.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-347843).
## Last eight quarters
| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [53.1](/filings/0001193125-25-281466.md) | [44.4 d](/filings/0001193125-26-127557.md) | [47.3](/filings/0001193125-26-222737.md) | [43.4](/filings/0001193125-26-347843.md) | [43.4](/filings/0001193125-25-281466.md) | [39.6 d](/filings/0001193125-26-127557.md) | [43.1](/filings/0001193125-26-222737.md) | [49.2](/filings/0001193125-26-347843.md) |
| Gross margin | % | [81.5%](/filings/0001193125-25-281466.md) | [76.3% d](/filings/0001193125-26-127557.md) | [79.7%](/filings/0001193125-26-222737.md) | [69.2%](/filings/0001193125-26-347843.md) | [70.6%](/filings/0001193125-25-281466.md) | [73.1% d](/filings/0001193125-26-127557.md) | [70.5%](/filings/0001193125-26-222737.md) | [73.1%](/filings/0001193125-26-347843.md) |
| Operating margin | % | [26.1%](/filings/0001193125-25-281466.md) | [10.6% d](/filings/0001193125-26-127557.md) | [51.1%](/filings/0001193125-26-222737.md) | [33.6%](/filings/0001193125-26-347843.md) | [36.6%](/filings/0001193125-25-281466.md) | [32.5% d](/filings/0001193125-26-127557.md) | [41.2%](/filings/0001193125-26-222737.md) | [38.5%](/filings/0001193125-26-347843.md) |
| Net margin | % | [5.3%](/filings/0001193125-25-281466.md) | [14.7% d](/filings/0001193125-26-127557.md) | [45.4%](/filings/0001193125-26-222737.md) | [5.7%](/filings/0001193125-26-347843.md) | [29.6%](/filings/0001193125-25-281466.md) | [35.9% d](/filings/0001193125-26-127557.md) | [26.3%](/filings/0001193125-26-222737.md) | [21.7%](/filings/0001193125-26-347843.md) |
| Diluted EPS | $ per share | [0.03](/filings/0001193125-25-281466.md) | not reported | [0.21](/filings/0001193125-26-222737.md) | [0.02](/filings/0001193125-26-347843.md) | [0.12](/filings/0001193125-25-281466.md) | not reported | [0.11](/filings/0001193125-26-222737.md) | [0.10](/filings/0001193125-26-347843.md) |
| Free cash flow | $m | [4.6 d](/filings/0001193125-25-281466.md) | [(7.9) d](/filings/0001193125-26-127557.md) | [1.7](/filings/0001193125-26-222737.md) | [(8.6) d](/filings/0001193125-26-347843.md) | [(20.9) d](/filings/0001193125-25-281466.md) | [51.2 d](/filings/0001193125-26-127557.md) | [9.1](/filings/0001193125-26-222737.md) | [22.4 d](/filings/0001193125-26-347843.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
## Last five fiscal years
| Line item | Unit | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [194](/filings/0001641172-25-001062.md) | [205](/filings/0001193125-26-127557.md) | [174](/filings/0001193125-26-127557.md) |
| Gross margin | % | [70.9%](/filings/0001641172-25-001062.md) | [76.0%](/filings/0001193125-26-127557.md) | [73.3%](/filings/0001193125-26-127557.md) |
| Operating margin | % | [36.5%](/filings/0001641172-25-001062.md) | [34.2%](/filings/0001193125-26-127557.md) | [38.9%](/filings/0001193125-26-127557.md) |
| Net margin | % | [20.3%](/filings/0001641172-25-001062.md) | [22.7%](/filings/0001193125-26-127557.md) | [29.4%](/filings/0001193125-26-127557.md) |
| Diluted EPS | $ per share | [0.42](/filings/0001641172-25-001062.md) | [0.48](/filings/0001193125-26-127557.md) | [0.50](/filings/0001193125-26-127557.md) |
| Free cash flow | $m | [42.1](/filings/0001641172-25-001062.md) | [18.0](/filings/0001193125-26-127557.md) | [23.3](/filings/0001193125-26-127557.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.
## Insider purchases and sales
The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sbc/insiders.md)
None in coverage.
## Funds that report holding it
From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Lumbard & Kellner, LLC](/funds/1602476.md) | 2026-06-30 | $5.3m | 1,727,208 | | Added +1,709,935 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.8m | 924,002 | | Added +504,362 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.3m | 427,864 | | Added +132,085 |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $551.1k | 178,929 | | Reduced −1,700 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $445.7k | 144,718 | | New +144,718 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $418.2k | 135,783 | | Reduced −456 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $404.1k | 131,204 | | Added +40,065 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $395.1k | 128,295 | | Added +64,748 |
| [Hillsdale Investment Management Inc.](/funds/1368465.md) | 2026-06-30 | $384.4k | 124,800 | | New +124,800 |
| [SEGALL BRYANT & HAMILL, LLC](/funds/1006378.md) | 2026-06-30 | $250.4k | 81,307 | | Unchanged |
## Recent filings
[All 232 filings](/companies/sbc/filings.md)
| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 07:00 ET | [10-Q](/filings/0001193125-26-347843.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347843 |
| 2026-08-13 | 06:50 ET | [8-K](/filings/0001193125-26-347825.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347825 |
| 2026-07-14 | 17:00 ET | [8-K](/filings/0001493152-26-033195.md) | 3.01 Delisting notice; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-033195 |
| 2026-05-28 | 06:09 ET | [DEF 14A](/filings/0001493152-26-025514.md) | Proxy statement, period 2026-05-28 | 0001493152-26-025514 |
| 2026-05-20 | 16:15 ET | [8-K](/filings/0001493152-26-024609.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-024609 |
| 2026-05-14 | 07:00 ET | [10-Q](/filings/0001193125-26-222737.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222737 |
| 2026-05-14 | 06:50 ET | [8-K](/filings/0001193125-26-222720.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-222720 |
| 2026-04-30 | 17:21 ET | [10-K/A](/filings/0001493152-26-020748.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-020748 |
| 2026-04-23 | 20:48 ET | [8-K](/filings/0001493152-26-018603.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-018603 |
| 2026-04-21 | 21:07 ET | [SCHEDULE 13D/A](/filings/0001493152-26-018402.md) | Ownership report, active investor, amended | 0001493152-26-018402 |
## Latest annual report
[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-127557.md), filed Mar 27, 2026.
## Forecast league
Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/acbfbf54-216a-4b04-a735-4e078b873aee)
## About the filer
- CIK: 1930313
- Tickers: SBC, SBCWW
- Exchange: Nasdaq
- SIC code: 8011 Services-Offices & Clinics of Doctors of Medicine
- State of incorporation: DE
- Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.